GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » Selling and Marketing Expense

NexImmune (NexImmune) Selling and Marketing Expense : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NexImmune Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. NexImmune's Selling and Marketing Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


NexImmune Selling and Marketing Expense Historical Data

The historical data trend for NexImmune's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Selling and Marketing Expense Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling and Marketing Expense
Get a 7-Day Free Trial - - - - -

NexImmune Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NexImmune Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NexImmune Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of NexImmune's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


NexImmune (NexImmune) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Executives
Alan S. Roemer director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover officer: VP, Corporate Controller C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao director 10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi director C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke officer: Chief Science Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones officer: Chief Operating Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis officer: EVP of R&D 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer director, officer: President and CEO C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer officer: Chief Financial Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight officer: Chief Medical Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877

NexImmune (NexImmune) Headlines